This project harnesses the E3 ligase KLHL12 for tumor-selective protein degradation. We designed and synthesized novel PROTACs , characterized their binding affinity and selectivity by biochemical assays, and performed quantitative proteomics to systematically evaluate degradation specificity, kinetics, and anti-tumor efficacy in cancer cell models.